JP2006083134A5 - - Google Patents

Download PDF

Info

Publication number
JP2006083134A5
JP2006083134A5 JP2004271927A JP2004271927A JP2006083134A5 JP 2006083134 A5 JP2006083134 A5 JP 2006083134A5 JP 2004271927 A JP2004271927 A JP 2004271927A JP 2004271927 A JP2004271927 A JP 2004271927A JP 2006083134 A5 JP2006083134 A5 JP 2006083134A5
Authority
JP
Japan
Prior art keywords
group
tga40s
diet
mice
restrained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004271927A
Other languages
English (en)
Japanese (ja)
Other versions
JP4993852B2 (ja
JP2006083134A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2004271927A external-priority patent/JP4993852B2/ja
Priority to JP2004271927A priority Critical patent/JP4993852B2/ja
Priority to PCT/JP2005/005623 priority patent/WO2006030553A1/en
Priority to US11/663,076 priority patent/US8202907B2/en
Priority to CA2579807A priority patent/CA2579807C/en
Priority to AU2005283697A priority patent/AU2005283697B9/en
Publication of JP2006083134A publication Critical patent/JP2006083134A/ja
Publication of JP2006083134A5 publication Critical patent/JP2006083134A5/ja
Priority to US13/465,546 priority patent/US8367729B2/en
Publication of JP4993852B2 publication Critical patent/JP4993852B2/ja
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004271927A 2004-09-17 2004-09-17 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 Expired - Fee Related JP4993852B2 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2004271927A JP4993852B2 (ja) 2004-09-17 2004-09-17 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
AU2005283697A AU2005283697B9 (en) 2004-09-17 2005-03-18 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
US11/663,076 US8202907B2 (en) 2004-09-17 2005-03-18 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
CA2579807A CA2579807C (en) 2004-09-17 2005-03-18 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
PCT/JP2005/005623 WO2006030553A1 (en) 2004-09-17 2005-03-18 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
US13/465,546 US8367729B2 (en) 2004-09-17 2012-05-07 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004271927A JP4993852B2 (ja) 2004-09-17 2004-09-17 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物

Publications (3)

Publication Number Publication Date
JP2006083134A JP2006083134A (ja) 2006-03-30
JP2006083134A5 true JP2006083134A5 (enExample) 2007-11-01
JP4993852B2 JP4993852B2 (ja) 2012-08-08

Family

ID=34963492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004271927A Expired - Fee Related JP4993852B2 (ja) 2004-09-17 2004-09-17 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物

Country Status (5)

Country Link
US (2) US8202907B2 (enExample)
JP (1) JP4993852B2 (enExample)
AU (1) AU2005283697B9 (enExample)
CA (1) CA2579807C (enExample)
WO (1) WO2006030553A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
KR20070044805A (ko) * 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
WO2008046870A1 (en) * 2006-10-19 2008-04-24 Nestec S.A. Long-term feed - cancer patient
KR101881982B1 (ko) * 2006-12-28 2018-07-25 산토리 홀딩스 가부시키가이샤 신경 재생제
WO2010032140A2 (en) 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
US9107891B2 (en) 2011-06-29 2015-08-18 Nippon Suisan Kaisha, Ltd. Method for alleviating fear memory
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1112820A (en) 1967-04-28 1968-05-08 Standard Telephones Cables Ltd Improvements in or relating to electrical storage systems
US4668704A (en) * 1982-08-09 1987-05-26 Regents Of The University Of California Method for protecting and healing gastro-duodenal mucosa and the liver of mammals
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JP3467794B2 (ja) 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
DK0707487T3 (da) 1993-06-09 2004-08-02 Martek Biosciences Corp Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser
CA2201931C (en) 1994-10-05 2004-08-10 Gerhard Kohn Mixture of phospholipid-containing fats and lcp fatty acids
JPH08143454A (ja) 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
US5583019A (en) * 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
JPH08214891A (ja) 1995-02-17 1996-08-27 Osaka City 高度不飽和脂肪酸含有トリグリセリドを含む油脂の製造方法
JPH0923817A (ja) 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
JPH0930962A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
CN1058845C (zh) 1996-01-31 2000-11-29 高世虎 强化营养豆奶粉
JP4034370B2 (ja) 1996-09-27 2008-01-16 雪印乳業株式会社 脳機能改善剤及び栄養組成物
JP4633204B2 (ja) 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
JPH10155459A (ja) 1996-11-27 1998-06-16 Suntory Ltd アスタキサンチン含有飲食物
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
DE69718455T2 (de) * 1997-07-22 2003-04-30 Societe Des Produits Nestle S.A., Vevey Lipidzusammensetzung für Säuglingsnährpräparat und Herstellungsverfahren
JP2970804B2 (ja) 1997-07-23 1999-11-02 株式会社フジクラ 難燃性シート
US6225444B1 (en) * 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
JP4175698B2 (ja) 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
DK1121115T4 (da) 1998-10-15 2011-01-10 Dsm Ip Assets Bv PUFA-tilskud
JP2001031586A (ja) 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
WO2001085158A2 (en) 2000-05-08 2001-11-15 Forskarpatent I Syd Ab Anandamide and structurally related lipids as vanilloid receptor modulators
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
AU2001265186A1 (en) 2000-05-30 2001-12-11 The Brigham And Women's Hospital, Inc. Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
AU2001266289A1 (en) 2000-06-23 2002-01-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
WO2002019839A1 (en) * 2000-09-07 2002-03-14 University Of Maryland Biotechnology Institute Use of arachidonic acid for enhanced culturing of fish larvae and broodstock
EP1239022B1 (fr) 2001-03-09 2009-05-06 Societe Des Produits Nestle S.A. Huile contenant un ou des acide(s) gras polyinsaturé(s) à longue chaîne issus de biomasse, procédé de Préparation, allment, composition nutritionnelle, cosmétique ou pharmaceutique la contenant
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
ES2386841T3 (es) 2001-06-18 2012-09-03 Neptune Technologies & Bioressources Inc. Extractos de krill para la prevención y/o el tratamiento de enfermedades cardiovasculares
CN101037641B (zh) 2001-07-02 2011-07-27 三得利控股株式会社 含有含多不饱和脂肪酸的甘油三酯的油或脂肪的生产方法
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
JP2003113120A (ja) 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
CA2485116C (en) 2002-05-03 2013-02-05 Pronova Biocare As Use of epa and dha in secondary prevention
WO2004024930A2 (en) 2002-09-13 2004-03-25 Suntory Limited Process for production of transesterified oils/fats or triglycerides
GB0221480D0 (en) 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
AU2003267818B2 (en) * 2002-09-24 2009-12-17 Suntory Holdings Limited Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities
EP1542688A4 (en) * 2002-09-26 2010-06-02 3M Innovative Properties Co 1H-imidazo dimers
EP1605930B1 (en) 2003-03-27 2020-06-03 Suntory Holdings Limited Use of arachidonic acid for normalization of infradian rhythm
CA2522712A1 (en) 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Nerve regenerating drug
GB2422373B (en) 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU2005208832A1 (en) 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
JP4868199B2 (ja) 2004-09-10 2012-02-01 学校法人鈴鹿医療科学大学 サルビアノール酸ｂを有効成分とする神経幹細胞増殖剤
JP2006083136A (ja) 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物

Similar Documents

Publication Publication Date Title
JP2006083134A5 (enExample)
JP2010501534A5 (enExample)
JP2007501762A5 (enExample)
EP2258177A3 (en) Mixtures comprising 1-methylcyclopropene
EP2149538A3 (en) Interface-infused nanotube interconnect
JP2013507321A5 (enExample)
JP2011507614A5 (enExample)
JP2008544074A5 (enExample)
JP2021507700A5 (enExample)
EP2695941A3 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
JP2009502199A5 (enExample)
JP2017048194A5 (enExample)
JP2008518879A5 (enExample)
EP3336182A3 (en) Modified phosphatases
WO2005079236A3 (en) Rna-mediated interference to control disease in terrestrial and aquaculture animals
JP2004530703A5 (enExample)
WO2010012442A3 (en) Insecticidal benzenedicarboxamide derivative
JP2012221259A5 (enExample)
IL188383A0 (en) Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
RU2007105390A (ru) Способ кормления собак
JP2014080432A5 (enExample)
JP2019218304A5 (enExample)
EP1602303A3 (en) Springing device particularly for mattresses
JP2006516278A5 (enExample)
JP2008513523A5 (enExample)